MicroRNAs Expression Profiles in Cardiovascular Diseases

Table 3

Circulating miRNAs as diagnostic markers for HF.

miRNAs	Regulation	Groups	Source	Methods	Reference
miR-24, -125b, -195, 199a, -214	Up	Human/6 HF, 4 controls	Left ventricle	Northern blot	[131]
miR-24, -125b, -195, 199a, -214	Up	Mice/3 Tg, 3 controls	Heart	Array, qRT-PCR
miR-214	Up	Human/19 ICM, 25 DCM, 13	Left ventricle	qTR-PCR	[11]
miR-19a/b	Downin DCM-AS	AS, 10 controls		Bead-based hybridization, qTR-PCR
miR-21, -129, -212	Up in fetal heart	Human/6 HF, 6 fetal hearts, 4 controls	Heart	Array, qRT-PCR	[130]
miR-100, -195	Up	Human/6 IDC, 5 ICM,	Heart	Array, qRT-PCR	[132]
miR-92, -133b	Down	6 controls
miR-125, -181b, -214, -342	Up	Human/50 end-stage HF	Left ventricle	Array	[126]
miR-1, -7, -29b, -378	Down	(DCM), 20 controls
32 miRs	Up	Human/17 HF, 10 post-LVAD, 10 controls	Heart	Array	[135]
miR-126	Up	Human/33 IHD (MI, UA, SA),	Plasma	qRT-PCR	[141]
miR-122, -499	No variation	10 HF, 17 controls
miR-126, -130a	Down	Human/45 CHF (ICM), 15 CHF (DCM), 35 controls	Angiogenic EOCs, CD34^+	Array, qRT-PCR	[142]
		Mice/8-16
miR-126	Down	Human/106 CHF: 55 ICM, 51 NICM; 30 controls	Mononuclear cells	Array	[145]
miR-508-5p	Up
miR-423-5p, -18*, -129-5p, miR-622, HS_202.1, -1254	Up	Human/30 HF, 20 HF with dyspnea, non-HF with dyspnea, 39 controls	Plasma	qRT-PCR	[118]
miR-423-5p, -320a, -22, -92b	Up	Human/30 chronic HF, 30 controls	Serum	qRT-PCR	[138]
miR-423-5p	No variation	Human/41 right ventricular HF, 10 controls	Plasma	qRT-PCR	[140]
miR-423-5p	Up	Human/45 DCM, 39 controls	Plasma	qRT-PCR	[139]
miR-103, -142-3p, -30b, -342-3p	Down	Human/32 HF, 15 COPD, 14 controls	Plasma	qRT-PCR	[137]
miR-499	Up	Human/33 HF, 34 controls	Plasma	qRT-PCR	[98]
miR-499	No variation	Human/15 CHF, 10 controls	Plasma	qRT-PCR	[97]
miR-107, -139, and -142-5p	Down in DCM and NIDCM	Human/15 ICM, 19 NCDCM, 19 controls	PBMCs	qRT-PCR	[144]
miR-142-3p and -29b	Up in NIDCM
miR-125b and -497	Down in DCM
miR-210	Up	Human/39 HF	Plasma	qRT-PCR	[146]
miR-210	Up	Human/13 CHF: 8 NYHA II, 5 NYHA III and IV; 6 controls	Mononuclear cells	qRT-PCR
miR-15a, -15b, -20a, -103, -130a, -130b, -195, -210, -301b, -451, -494	Up	Rat/13HF, 9 controls	Plasma	Array
miR-210, -30a	Up	Human/22 HF, 18 controls, 9 fetuses	Serum	qRT-PCR	[147]
miR-133a	Up	Human/74 AS	Plasma, LV biopsies	qRT-PCR	[153]
miR-21	Up	Human/75 AS, 32 surgical patients, 25 controls	Plasma, LV biopsies	qRT-PCR, in situ	[154]
				hybridization
miR-122	Down	Human/28 AS: 15 SF, 13 non-SF; 10 controls	Endomyocardial biopsies	qRT-PCR	[155]

AP: angina pectoris; AS: aortic stenosis; CHF: chronic heart failure; COPD: chronic obstructive pulmonary disease; DCM: dilated cardiomyopathy; Down: downregulated; EOCs: early outgrowth cells; HF: heart failure; ICM: ischemic cardiomyopathy; IDC: idiopathic cardiomyopathy; IHD: ischemic heart disease; ISC: ischemic cardiomyopathy; LVAD: left ventricular assist device; MI: myocardial infarction; miR: microRNA; NICM: nonischemic cardiomyopathy; NIDCM: nonischemic dilated cardiomyopathy; non-SF: nonsevere fibrosis; NYHA: New York Heart Association; qRT-PCR: quantitative real-time polymerase chain reaction; SA: stable angina; SF: severe fibrosis; UA: unstable angina; Up: upregulated.